{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:59:30Z","timestamp":1781715570993,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/emm.2017.104","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T07:01:14Z","timestamp":1501225274000},"page":"e360-e360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy"],"prefix":"10.1038","volume":"49","author":[{"given":"Hyung Bae","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Mi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"BFemm2017104_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrc2804","volume":"10","author":"RR Jenq","year":"2010","unstructured":"Jenq RR, van den Brink MR . Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10: 213\u2013221.","journal-title":"Nat Rev Cancer"},{"key":"BFemm2017104_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nri3226","volume":"12","author":"HW Li","year":"2012","unstructured":"Li HW, Sykes M . Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol 2012; 12: 403\u2013416.","journal-title":"Nat Rev Immunol"},{"key":"BFemm2017104_CR3","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood.V90.8.3204","volume":"90","author":"GR Hill","year":"1997","unstructured":"Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL . Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204\u20133213.","journal-title":"Blood"},{"issue":"3A","key":"BFemm2017104_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1083-8791(00)70056-5","volume":"6","author":"TR Spitzer","year":"2000","unstructured":"Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6 (3A): 309\u2013320.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFemm2017104_CR5","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1182\/blood-2011-08-372508","volume":"118","author":"H Liu","year":"2011","unstructured":"Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011; 118: 6438\u20136445.","journal-title":"Blood"},{"key":"BFemm2017104_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2009-03-211441","volume":"114","author":"HE Kohrt","year":"2009","unstructured":"Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114: 1099\u20131109.","journal-title":"Blood"},{"key":"BFemm2017104_CR7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555\u2013562.","journal-title":"Blood"},{"key":"BFemm2017104_CR8","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/sj.leu.2404333","volume":"20","author":"WI Bensinger","year":"2006","unstructured":"Bensinger WI . The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2006; 20: 1683\u20131689.","journal-title":"Leukemia"},{"key":"BFemm2017104_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.bbmt.2010.05.005","volume":"16","author":"EP Alyea","year":"2010","unstructured":"Alyea EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepiorka D, Sadelin M et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010; 16: 1037\u20131069.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFemm2017104_CR10","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","volume":"76","author":"HJ Kolb","year":"1990","unstructured":"Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462\u20132465.","journal-title":"Blood"},{"key":"BFemm2017104_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","volume":"15","author":"RH Collins Jr.","year":"1997","unstructured":"Collins RH Jr., Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433\u2013444.","journal-title":"J Clin Oncol"},{"key":"BFemm2017104_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14712598.2011.554811","volume":"11","author":"C Roddie","year":"2011","unstructured":"Roddie C, Peggs KS . Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011; 11: 473\u2013487.","journal-title":"Expert Opin Biol Ther"},{"key":"BFemm2017104_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/sj.bmt.1703883","volume":"31","author":"AM Raiola","year":"2003","unstructured":"Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687\u2013693.","journal-title":"Bone Marrow Transplant"},{"key":"BFemm2017104_CR14","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"C Schmid","year":"2007","unstructured":"Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938\u20134945.","journal-title":"J Clin Oncol"},{"key":"BFemm2017104_CR15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.V95.8.2645","volume":"95","author":"DL Porter","year":"2000","unstructured":"Porter DL, Collins RH Jr., Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214\u20131221.","journal-title":"Blood"},{"key":"BFemm2017104_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/bmt.2015.288","volume":"51","author":"X Chang","year":"2016","unstructured":"Chang X, Zang X, Xia CQ . New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant 2016; 51: 324\u2013332.","journal-title":"Bone Marrow Transplant"},{"key":"BFemm2017104_CR17","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550\u20131561.","journal-title":"Lancet"},{"key":"BFemm2017104_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.critrevonc.2005.07.001","volume":"57","author":"DH Fowler","year":"2006","unstructured":"Fowler DH . Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 2006; 57: 225\u2013244.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFemm2017104_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.bbmt.2004.07.006","volume":"10","author":"P Hari","year":"2004","unstructured":"Hari P, Logan B, Drobyski WR . Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia\/graft-versus-host reactivity? Biol Blood Marrow Transplant 2004; 10: 743\u2013747.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFemm2017104_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nri2000","volume":"7","author":"WD Shlomchik","year":"2007","unstructured":"Shlomchik WD . Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340\u2013352.","journal-title":"Nat Rev Immunol"},{"key":"BFemm2017104_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M . Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443\u2013458.","journal-title":"Nat Rev Immunol"},{"key":"BFemm2017104_CR22","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2002-01-0023","volume":"100","author":"MY Mapara","year":"2002","unstructured":"Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M . Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002; 100: 1903\u20131909.","journal-title":"Blood"},{"key":"BFemm2017104_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbmt.2012.12.013","volume":"19","author":"P Krishnamurthy","year":"2013","unstructured":"Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013; 19: 562\u2013568.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFemm2017104_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/JCI200316950","volume":"111","author":"YM Kim","year":"2003","unstructured":"Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M . Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003; 111: 659\u2013669.","journal-title":"J Clin Invest"},{"key":"BFemm2017104_CR25","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1182\/blood-2007-05-087940","volume":"110","author":"PA Taylor","year":"2007","unstructured":"Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood 2007; 110: 3480\u20133488.","journal-title":"Blood"},{"key":"BFemm2017104_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","volume":"276","author":"C Bonini","year":"1997","unstructured":"Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719\u20131724.","journal-title":"Science"},{"key":"BFemm2017104_CR27","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1182\/blood-2006-05-023416","volume":"109","author":"F Ciceri","year":"2007","unstructured":"Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007; 109: 4698\u20134707.","journal-title":"Blood"},{"key":"BFemm2017104_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365: 1673\u20131683.","journal-title":"N Engl J Med"},{"key":"BFemm2017104_CR29","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","volume":"125","author":"X Zhou","year":"2015","unstructured":"Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 2015; 125: 4103\u20134113.","journal-title":"Blood"},{"key":"BFemm2017104_CR30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","volume":"117","author":"CG Brunstein","year":"2011","unstructured":"Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061\u20131070.","journal-title":"Blood"},{"key":"BFemm2017104_CR31","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","volume":"117","author":"M Di Ianni","year":"2011","unstructured":"Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921\u20133928.","journal-title":"Blood"},{"key":"BFemm2017104_CR32","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579\u20131586.","journal-title":"Lancet"},{"key":"BFemm2017104_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3324\/haematol.2010.038356","volume":"96","author":"JA Perez-Simon","year":"2011","unstructured":"Perez-Simon JA, Lopez-Villar O, Andreu EJ, Rifon J, Muntion S, Diez Campelo M et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I\/II clinical trial. Haematologica 2011; 96: 1072\u20131076.","journal-title":"Haematologica"},{"key":"BFemm2017104_CR34","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nri1729","volume":"5","author":"MH Kershaw","year":"2005","unstructured":"Kershaw MH, Teng MW, Smyth MJ, Darcy PK . Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005; 5: 928\u2013940.","journal-title":"Nat Rev Immunol"},{"issue":"R1","key":"BFemm2017104_CR35","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1093\/hmg\/ddr102","volume":"20","author":"MC Ngo","year":"2011","unstructured":"Ngo MC, Rooney CM, Howard JM, Heslop HE . Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet 2011; 20 (R1): R93\u2013R99.","journal-title":"Hum Mol Genet"},{"key":"BFemm2017104_CR36","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1182\/blood-2011-09-380519","volume":"119","author":"JH Shin","year":"2012","unstructured":"Shin JH, Park HB, Oh YM, Lim DP, Lee JE, Seo HH et al. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood 2012; 119: 5678\u20135687.","journal-title":"Blood"},{"key":"BFemm2017104_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1600-065X.2008.00649.x","volume":"224","author":"KS Peggs","year":"2008","unstructured":"Peggs KS, Quezada SA, Allison JP . Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008; 224: 141\u2013165.","journal-title":"Immunol Rev"},{"key":"BFemm2017104_CR38","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP . Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734\u20131736.","journal-title":"Science"},{"key":"BFemm2017104_CR39","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517\u20132526.","journal-title":"N Engl J Med"},{"key":"BFemm2017104_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4252\/wjsc.v3.i8.70","volume":"3","author":"MS Jeon","year":"2011","unstructured":"Jeon MS, Yi TG, Lim HJ, Moon SH, Lee MH, Kang JS et al. Characterization of mouse clonal mesenchymal stem cell lines established by subfractionation culturing method. World J Stem Cells 2011; 3: 70\u201382.","journal-title":"World J Stem Cells"},{"key":"BFemm2017104_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1705644","volume":"39","author":"CK Min","year":"2007","unstructured":"Min CK, Kim BG, Park G, Cho B, Oh IH . IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 637\u2013645.","journal-title":"Bone Marrow Transplant"},{"key":"BFemm2017104_CR42","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2006-03-007427","volume":"108","author":"R Chakraverty","year":"2006","unstructured":"Chakraverty R, Eom HS, Sachs J, Buchli J, Cotter P, Hsu R et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 2006; 108: 2106\u20132113.","journal-title":"Blood"},{"key":"BFemm2017104_CR43","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.4049\/jimmunol.1200045","volume":"189","author":"HW Li","year":"2012","unstructured":"Li HW, Sachs J, Pichardo C, Bronson R, Zhao G, Sykes M . Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli. J Immunol 2012; 189: 5572\u20135581.","journal-title":"J Immunol"},{"key":"BFemm2017104_CR44","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.4049\/jimmunol.165.8.4246","volume":"165","author":"HM Hu","year":"2000","unstructured":"Hu HM, Winter H, Urba WJ, Fox BA . Divergent roles for CD4+ T cells in the priming and effector\/memory phases of adoptive immunotherapy. J Immunol 2000; 165: 4246\u20134253.","journal-title":"J Immunol"},{"key":"BFemm2017104_CR45","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.4049\/jimmunol.164.7.3902","volume":"164","author":"CN Baxevanis","year":"2000","unstructured":"Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M . Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000; 164: 3902\u20133912.","journal-title":"J Immunol"},{"key":"BFemm2017104_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2007.11.014","volume":"2","author":"G Ren","year":"2008","unstructured":"Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141\u2013150.","journal-title":"Cell Stem Cell"},{"key":"BFemm2017104_CR47","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/eji.200738129","volume":"38","author":"D Polchert","year":"2008","unstructured":"Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745\u20131755.","journal-title":"Eur J Immunol"},{"key":"BFemm2017104_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12185-015-1920-z","volume":"103","author":"Y Miura","year":"2016","unstructured":"Miura Y . Human bone marrow mesenchymal stromal\/stem cells: current clinical applications and potential for hematology. Int J Hematol 2016; 103: 122\u2013128.","journal-title":"Int J Hematol"},{"key":"BFemm2017104_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.imlet.2012.01.015","volume":"143","author":"W Chen","year":"2012","unstructured":"Chen W, Li M, Li Z, Yan Z, Cheng H, Pan B et al. CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease. Immunol Lett 2012; 143: 161\u2013169.","journal-title":"Immunol Lett"},{"key":"BFemm2017104_CR50","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/stem.1656","volume":"32","author":"H Li","year":"2014","unstructured":"Li H, Jiang Y, Jiang X, Guo X, Ning H, Li Y et al. CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: a novel approach to separate GvHD from GvL effect. Stem Cells 2014; 32: 1890\u20131903.","journal-title":"Stem Cells"},{"key":"BFemm2017104_CR51","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo NP, Dudley ME, Rosenberg SA . Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12: 269\u2013281.","journal-title":"Nat Rev Immunol"},{"key":"BFemm2017104_CR52","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925\u2013935.","journal-title":"Blood"},{"key":"BFemm2017104_CR53","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507\u20131517.","journal-title":"N Engl J Med"},{"key":"BFemm2017104_CR54","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1074-7613(00)80406-9","volume":"7","author":"CA Chambers","year":"1997","unstructured":"Chambers CA, Sullivan TJ, Allison JP . Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 1997; 7: 885\u2013895.","journal-title":"Immunity"},{"key":"BFemm2017104_CR55","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/ni.2079","volume":"12","author":"S Feau","year":"2011","unstructured":"Feau S, Arens R, Togher S, Schoenberger SP . Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat Immunol 2011; 12: 908\u2013913.","journal-title":"Nat Immunol"},{"key":"BFemm2017104_CR56","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985\u2013988.","journal-title":"Science"},{"key":"BFemm2017104_CR57","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/stem.1867","volume":"33","author":"JJ Auletta","year":"2015","unstructured":"Auletta JJ, Eid SK, Wuttisarnwattana P, Silva I, Metheny L, Keller MD et al. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Stem Cells 2015; 33: 601\u2013614.","journal-title":"Stem Cells"},{"key":"BFemm2017104_CR58","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.bbmt.2010.01.011","volume":"16","author":"F Baron","year":"2010","unstructured":"Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16: 838\u2013847.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFemm2017104_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.stem.2010.09.009","volume":"7","author":"K English","year":"2010","unstructured":"English K, French A, Wood KJ . Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 2010; 7: 431\u2013442.","journal-title":"Cell Stem Cell"},{"key":"BFemm2017104_CR60","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbmt.2008.03.012","volume":"15","author":"P Kebriaei","year":"2009","unstructured":"Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 804\u2013811.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFemm2017104_CR61","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","volume":"20","author":"J Kurtzberg","year":"2014","unstructured":"Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 2014; 20: 229\u2013235.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFemm2017104_CR62","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1073\/pnas.0910720107","volume":"107","author":"K Nemeth","year":"2010","unstructured":"Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107: 5652\u20135657.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFemm2017104_CR63","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1600-0609.2011.01635.x","volume":"87","author":"J Guo","year":"2011","unstructured":"Guo J, Yang J, Cao G, Fan H, Guo C, Ma YE et al. Xenogeneic immunosuppression of human umbilical cord mesenchymal stem cells in a major histocompatibility complex-mismatched allogeneic acute graft-versus-host disease murine model. Eur J Haematol 2011; 87: 235\u2013243.","journal-title":"Eur J Haematol"},{"key":"BFemm2017104_CR64","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2015.01.036","volume":"148","author":"M Dave","year":"2015","unstructured":"Dave M, Hayashi Y, Gajdos GB, Smyrk TC, Svingen PA, Kvasha SM et al. Stem cells for murine interstitial cells of cajal suppress cellular immunity and colitis via prostaglandin E2 secretion. Gastroenterology 2015; 148: 978\u2013990.","journal-title":"Gastroenterology"},{"key":"BFemm2017104_CR65","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/mt.2015.67","volume":"23","author":"R Chinnadurai","year":"2015","unstructured":"Chinnadurai R, Copland IB, Ng S, Garcia M, Prasad M, Arafat D et al. Mesenchymal stromal cells derived from Crohn's patients deploy indoleamine 2,3-dioxygenase-mediated immune suppression, independent of autophagy. Mol Ther 2015; 23: 1248\u20131261.","journal-title":"Mol Ther"},{"key":"BFemm2017104_CR66","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-13-1656","volume":"74","author":"W Ling","year":"2014","unstructured":"Ling W, Zhang J, Yuan Z, Ren G, Zhang L, Chen X et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res 2014; 74: 1576\u20131587.","journal-title":"Cancer Res"},{"key":"BFemm2017104_CR67","doi-asserted-by":"publisher","first-page":"7787","DOI":"10.4049\/jimmunol.0902318","volume":"183","author":"Q Zhang","year":"2009","unstructured":"Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183: 7787\u20137798.","journal-title":"J Immunol"},{"key":"BFemm2017104_CR68","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.exphem.2012.05.006","volume":"40","author":"X Qu","year":"2012","unstructured":"Qu X, Liu X, Cheng K, Yang R, Zhao RC . Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. Exp Hematol 2012; 40: 761\u2013770.","journal-title":"Exp Hematol"},{"key":"BFemm2017104_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13287-015-0271-2","volume":"7","author":"J Leibacher","year":"2016","unstructured":"Leibacher J, Henschler R . Biodistribution, migration and homing of systemically applied mesenchymal stem\/stromal cells. Stem Cell Res Ther 2016; 7: 7.","journal-title":"Stem Cell Res Ther"}],"container-title":["Experimental & Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/emm2017104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/emm2017104","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/emm.2017.104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/emm2017104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:20:49Z","timestamp":1684430449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/emm2017104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFemm2017104"],"URL":"https:\/\/doi.org\/10.1038\/emm.2017.104","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"23 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}